国药现代(600420.SH)：子公司获得化学原料药上市申请批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient, Sitagliptin Phosphate, which is primarily used for improving blood sugar control in patients with type 2 diabetes [1] Company Summary - The company involved is Sinopharm Modern (国药现代), which is a subsidiary of Sinopharm Group [1] - The approved product, Sitagliptin Phosphate, is classified as a DPP-4 inhibitor [1] Industry Summary - Sitagliptin Phosphate is utilized in the clinical management of type 2 diabetes, indicating a focus on diabetes treatment within the pharmaceutical industry [1]